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Abstract
Background: Burkholderia pseudomallei is the causative agent of melioidosis, a severe invasive disease of humans
and animals. Initial screening of a B. pseudomallei signature-tagged mutagenesis library identified an attenuated
mutant with a transposon insertion in a gene encoding the sensor component of an uncharacterised two-component
signal transduction system (TCSTS), which we designated BprRS.
Results: Single gene inactivation of either the response regulator gene (bprR) or the sensor histidine kinase gene (bprS)
resulted in mutants with reduced swarming motility and reduced virulence in mice. However, a bprRS double mutant
was not attenuated for virulence and displayed wild-type levels of motility. The transcriptomes of the bprS, bprR and
bprRS mutants were compared with the transcriptome of the parent strain K96243. Inactivation of the entire BprRS
TCSTS (bprRS double mutant) resulted in altered expression of only nine genes, including both bprR and bprS, five
phage-related genes and bpss0686, encoding a putative 5, 10-methylene tetrahydromethanopterin reductase involved
in one carbon metabolism. In contrast, the transcriptomes of each of the bprR and bprS single gene mutants revealed
more than 70 differentially expressed genes common to both mutants, including regulatory genes and those required
for flagella assembly and for the biosynthesis of the cytotoxic polyketide, malleilactone.
Conclusions: Inactivation of the entire BprRS TCSTS did not alter virulence or motility and very few genes were
differentially expressed indicating that the definitive BprRS regulon is relatively small. However, loss of a single
component, either the sensor histidine kinase BprS or its cognate response regulator BprR, resulted in significant
transcriptomic and phenotypic differences from the wild-type strain. We hypothesize that the dramatically altered
phenotypes of these single mutants are the result of cross-regulation with one or more other TCSTSs and
concomitant dysregulation of other key regulatory genes.
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Background
Burkholderia pseudomallei is a highly pathogenic Gram-
negative organism and the causative agent of melioid-
osis, a potentially fatal infectious disease of humans and
animals. The bacterium is endemic to tropical regions
including South East Asia and Northern Australia; mor-
tality rates resulting from melioidosis remain extremely
high, with up to 42 % mortality in the Northeastern
region of Thailand and 14 % mortality in Australia’s
Northern Territory [1, 2]. Importantly, a 90 % mortality
rate is associated with septic shock [3]. In Northern
Australia, melioidosis accounts for 32 % of community-
acquired bacteraemic pneumonia and 6 % of all bacter-
aemias [4], while in the Northeastern region of Thailand,
the disease accounts for 20 % of all community-acquired
septicaemias [5] and is the third most common cause of
death from an infectious disease [2]. The complex clin-
ical spectrum of melioidosis, the potentially rapid pro-
gression of disease and the fact that B. pseudomallei is
innately resistant to a wide range of antimicrobial agents
[6–8] makes treatment of this disease difficult.
For B. pseudomallei and most other opportunistic
pathogens, the ability to sense external signals is critical
for the transition from their environmental niche into
the eukaryotic host, as well as for survival within specific
niches within the host. Prokaryotic two-component sig-
nal transduction systems (TCSTS) constitute a critical
set of regulators which act to sense environmental sig-
nals and respond by altering gene expression [9–11].
TCSTS generally consist of a membrane-bound sensor
kinase (SK) and a cytosolic DNA-binding response regu-
lator (RR) [11]. The SK protein senses extracellular stim-
uli and responds through the autophosphorylation of a
specific histidine residue. This phosphoryl group is then
transferred to an aspartate residue on the cytoplasmic
RR leading to a conformational change that activates the
RR, resulting in the altered expression of a specific set of
genes [12]. TCSTS components are promising drug
targets as these systems are not present in mammalian
cells and inhibitors that target TCSTSs are likely to
function in a manner distinct from existing antimicrobial
agents, thereby providing an alternative treatment for
multidrug resistant bacteria [13]. Moreover, many
TCSTS regulate expression of virulence genes and there-
fore drugs that target TCSTS could reduce virulence
without affecting bacterial viability and thus reduce the
development of antimicrobial resistance during treat-
ment regimens [14].
The genome of B. pseudomallei strain K96243 encodes
more than 60 TCSTS [15] but only a few have been
characterized including BPSL2024-5, VirAG, MrgRS and
IrlRS. The IrlRS system is involved in the regulation of
B. pseudomallei invasion of epithelial cells as well as
heavy metal resistance. However, an irlR mutant was not
attenuated for virulence in the C57BL/6 mouse, infant
diabetic rat and Syrian hamster models [16, 17]. The
MrgRS system responds to temperature, with increased
expression of mrgR and mrgS observed during growth at
37 °C compared to 25 °C. This system may be involved
in pathogenesis, but its role in virulence has not been
specifically tested [18]. The VirAG system regulates the
expression of the type VI secretion system cluster 1
(T6SS-1) during growth within macrophages. Both a
virG mutant and a T6SS-1 mutant were attenuated for
virulence [19]. The gene bpsl2025, encoding the SK of a
TCSTS, was first identified in an in vivo hamster infec-
tion microarray study and a directed bpsl2025 mutant
was significantly attenuated in the hamster model (≥3-
log increase in ID50) [20].
Here we characterise a TCSTS in B. pseudomallei that
we have named BprRS. Inactivation of the entire BprRS
system via inactivation of both genes had no effect on
virulence or motility and RNA expression analysis of the
double bprRS mutant revealed few changes in gene
expression. However, inactivation of only one compo-
nent (either bprR or bprS) led to an attenuated pheno-
type in both virulence and motility. High-throughput
RNA sequencing (RNA-seq) comparing the transcrip-
tomes of the bprS and bprR mutants with the parent
strain of B. pseudomallei revealed a large number of ex-
pression changes in genes required for chemotaxis, fla-
gella biosynthesis and production of malleilactone.
Furthermore, many transcriptional regulators were also
differentially expressed in the single gene mutant strains.
We propose that the altered phenotypes displayed by the
bprR and bprS single mutants are due to the orphaned
sensor or the orphaned response regulator (respectively)
engaging in cross-talk interactions with one or more of
the other B. pseudomallei TCSTS.
Results
Identification of an attenuated B. pseudomallei bprS
(bpss0687) signature-tagged transposon mutant
A signature-tagged library of 336 B. pseudomallei
K96243 mutants was constructed and screened for re-
duced in vivo growth in the acute (BALB/c) mouse meli-
oidosis model. Mutants displaying reduced hybridisation
in the output pools were tested individually for an in
vivo growth defect by competitive growth assays. Five
mutants were identified that displayed a statistically sig-
nificant in vivo growth defect (P < 0.001). Four of the at-
tenuated mutants contained transposon insertions
within genes required for the biosynthesis of 1,3-linked
2-O-acetyl-6-deoxy-β-D-manno-heptopyranose capsular
polysaccharide (three in wzm2, one in wcbQ). This locus
has previously been shown to be important for B. pseu-
domallei virulence [21, 22]. The fifth attenuated mutant
contained a Tn5 insertion within bpss0687 (112 bp from
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the 3′ end) and this mutant was designated bprS::Tn5
(Fig. 1a). The presence of a single transposon insertion
in this mutant was confirmed by Southern blot analysis
(data not shown). The ID50 of the B. pseudomallei par-
ent strain K96243 and the bprS::Tn5 mutant was deter-
mined in groups of five BALB/c mice following
inoculation via the intranasal (i.n.) or intraperitoneal
(i.p.) routes of infection. For the i.n. route of infection,
the ID50 of the bprS::Tn5 mutant was >1.3 × 10
7 CFU
while the parent strain K96243 was <1.2 × 104 CFU. For
the i.p. route of infection, the ID50 of the bprS::Tn5 mu-
tant was >1.6 × 104 CFU compared with <1.2 × 103 CFU
for the parent strain K96243. Therefore, the bprS::Tn5
mutant was attenuated for virulence via both infection
routes in BALB/c mice. Importantly, the bprS::Tn5 mu-
tant displayed normal in vitro growth in both rich
medium (2YT) and minimal medium (M9) indicating
that the attenuated phenotype was not due to a general
growth defect (data not shown).
Bioinformatic analysis of BPSS0687 revealed that the
predicted protein sequence displayed significant amino
acid identity to a number of characterised histidine ki-
nases, including QseC from Pseudomonas spp. (92 %
coverage, 39 % identity). Several conserved amino acid
domains were identified within the predicted SK, includ-
ing a catalytic histidine kinase-like ATPase, C-terminal
domain (HATPase_c), a histidine kinase A domain
(HisKA), a HAMP (histidine kinases, adenylyl cyclases,
methyl-accepting chemotaxis proteins, and phospha-
tases) signal transduction domain and two transmem-
brane regions flanking the predicted stimulus-specific
region (Fig. 1a). Located immediately upstream of the
histidine kinase gene was a gene encoding a protein with
receiver and effector domains typical of a RR (bpss0688).
RT-PCR using primers that spanned the two genes indi-
cated that bpss0687 and bpss0688 were co-transcribed
(data not shown). Together these data indicate that
bpss0687 and bpss0688 encode a cognate TCSTS pair
named BprRS.
Generation of directed bprS, bprR and bprRS mutants and
associated virulence studies
To confirm that inactivation of bprS led to an attenuated
phenotype, a directed bprS mutant was constructed
using double-crossover insertional mutagenesis (Fig. 1a).
We first compared the growth of the parent strain
K96243 and the mutant in BALB/c mice using competi-
tive growth assays. The bprS mutant displayed normal in
vitro growth (data not shown) but the in vivo competi-
tive index of the bprS mutant was 0.094 ± 0.08, indicative
of an approximately 10-fold reduced growth rate in vivo
compared to the parent strain. The attenuated pheno-
type was then confirmed using virulence trials in BALB/
c mice (Fig. 2). Mice infected with the parent strain
K96243 displayed signs of illness by 28–50 h (days 2–3)
and eight of the nine mice were euthanized by 190 h
(day 8) after infection. In contrast, the survival rate in
the group infected with the bprS mutant was signifi-
cantly increased (Fisher’s exact test; P = 0.015), with only
two mice developing late stage signs of infection and re-
quired euthanasia after 190 h.
Fig. 1 Schematic representation of the bprR (bpss0688) and bprS (bpss0687) genes in the B. pseudomallei K96243 wild-type strain and each of the bprS
and bprR mutants. Panel a, organisation of the bprRS genes in B. pseudomallei wild-type showing the conserved amino acid domains encoded within
each gene. Domains shown are the receiver and effector domains within bprR and, within bprS, the following domains: transmembrane regions 1 and
2 (TMR1 and 2) between which the stimulus-specific region is located, the HAMP (histidine kinases, adenylyl cyclases, methyl-accepting chemotaxis
proteins, and phosphatases) signal transduction domain, the HisKA (histidine kinase A) dimerization/phosphoacceptor domain and the HATPase_c
(histidine kinase-like ATPase catalytic) domain. The relative position of the insertion in each of the single mutants is shown below the gene schematic.
Panel b, schematic representation of the regions remaining in each gene and the relative position of the tetracycline gene cassette in the bprRS
double mutant
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To further characterise the BprRS TCSTS, a directed
bprR mutant (Fig. 1a) and a bprRS double mutant
(Fig. 1b) were also constructed by double-crossover in-
sertional mutagenesis. The bprR mutant was also highly
attenuated for virulence (P = 0.003) with only a single
mouse showing late-stage disease signs at 150 h (day 6)
(Fig. 2). In contrast, the bprRS mutant was not attenu-
ated for virulence as determined by numbers of surviv-
ing mice (Fisher’s exact test; P = 0.13) or time to
euthanasia (Log-rank Mantel-Cox test; P = 0.062) (Fig. 2).
These data clearly show that separate inactivation of
BprRS TCSTS SK or the RR resulted in decreased viru-
lence, but inactivation of both genes in the BprRS
TCSTS system did not.
Transcriptomic analyses of the bprRS double mutant
TCSTS are critical regulators of bacterial gene expres-
sion. To understand why the bprRS mutant was not at-
tenuated for virulence, while the single bprR and bprS
mutants were, we analysed the transcriptomes of all
three mutant strains and the wild-type strain. Firstly, to
identify the genes controlled by the BprRS system we
compared the transcriptomes of the bprRS double mu-
tant and the parent strain, K96243. In total, only nine
genes were differentially expressed (five with increased
and four with decreased expression) in the bprRS double
mutant (Table 1). Both the truncated bprR and bprS
gene fragments showed increased expression, suggesting
that the BprRS TCSTS likely regulates its own expres-
sion. Two genes, bpss0686 and bpss0686a, located im-
mediately upstream of the bprRS TCSTS genes but
transcribed from the other strand, showed increased ex-
pression in the bprRS double mutant (Table 1); these
genes were also identified as differentially expressed in
the bprS single mutant (Table 2). Bioinformatic analyses
of bpss0686a revealed no additional information on the
open reading frame and analysis of the RNA-seq data re-
vealed that only a single sequence read of the 13 million
sequence reads generated from the parent strain
(K96243) matched this region, indicating that bpss0686a
may not encode a functional protein, or it is not
expressed under the conditions used for bacterial
growth. Bioinformatic analysis of bpss0686 revealed that
it encoded a putative enzyme belonging to the flavin-
utilizing monoxygenase super family and the nitrilotria-
cetate monoxgenase sub-family. Moreover, the encoded
protein had 65 % identity (96 % coverage) to the 5, 10-
methylene tetrahydromethanopterin reductase in Methy-
lobacterium extorquens that is required for one carbon
metabolism [23]. Five phage-associated genes were also
differentially expressed in the bprRS double mutant; four
of these showed decreased expression and one, encoding
a phage membrane protein (bpss1087), showed increased
expression. Three of the phage genes, bpss1087 and
bpss1066 (encoding a predicted phage terminase/endo-
nuclease subunits), and bpss1072 (encoding a protein of
Fig. 2 Kaplan-Meier survival curves for groups of mice infected
intranasally with the B. pseudomallei wild-type or the bprS, bprR
or bprRS mutant strains. Mice were infected with the following
doses; wild-type strain, 6 × 104 CFU; bprS mutant, 8 × 104 CFU,
bprR mutant, 3 × 104 CFU, bprRS mutant 9 × 104 CFU
Table 1 Genes with differential expression in the bprRS double mutant compared to expression in the wild-type parent strain
Locus tag Gene product/description bprRS mutant Expression (log2) FDR
Increased expression in bprRS double mutant relative to wild-type expression
BPSS0686 putative 5, 10-methylenetetrahydro-methanopterin reductase 3.36 3.21E-07
BPSS0686a protein of unknown function 5.63 7.35E-05
BPSS0687 BprS-sensor kinase protein 4.34 1.67E-07
BPSS0688 BprR-response regulator protein 2.07 1.31E-05
BPSS1087 phage membrane protein 1.13 3.41E-03
Decreased expression in bprRS double mutant relative to wild-type expression
BPSL0145 protein of unknown function with ATPase domain, putative phage-encoded −5.17 1.17E-04
BPSL0146 membrane protein −3.48 9.28E-06
BPSS1066 phage terminase, endonuclease subunit −3.62 2.86E-03
BPSS1072 phage-acquired protein −4.89 9.28E-06
Genes were identified as differentially expressed if they showed >2-fold expression change (log2 > 1.0 or log2 < −1.0) compared to the wild-type strain with a False
Discovery Rate (FDR) of <0.01
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Table 2 Genes with increased expression in either the bprR and/or bprS single mutants
Locus tag Gene
name
Description bprS mutant
Expression (log2)
bprS
mutant FDR
bprR mutant
Expression (log2)
bprR
mutant FDR
BPSL0026 fliL flagellar basal body-associated protein FliL 2.09 8.28E-03 1.82# 1.52E-02
BPSL0028 fliN flagellar motor switch protein 2.25 5.34E-03 1.94 9.47E-03
BPSL0031 fliQ flagellar biosynthesis protein 2.15 5.34E-03 1.93# 1.08E-02
BPSL0067 protein of unknown function 2.54 2.16E-05 2.30 2.20E-05
BPSL0068 putative lipoprotein 2.46 2.16E-05 2.30 2.11E-05
BPSL0069 putative anti-sigma factor 1.02 4.78E-03 0.89 1.09E-02
BPSL0071 putative catalase 1.31 4.26E-03 1.47 2.44E-03
BPSL0225 putative flagellar hook-length control protein 1.76 1.24E-03 1.24 6.62E-03
BPSL0226 fliJ flagellar fliJ protein 1.87 1.75E-03 1.34# 1.09E-02
BPSL0227 fliI flagellum-specific ATP synthase 1.94 5.34E-03 1.54# 1.32E-02
BPSL0228 fliH flagellar assembly protein H 2.04 8.43E-03 1.69# 1.69E-02
BPSL0230 fliF flagellar MS-ring protein 2.14 8.20E-03 1.75# 1.64E-02
BPSL0231 fliE flagellar hook-basal body complex protein 1.81 8.84E-03 1.39# 2.52E-02
BPSL0269 flgA flagellar basal body P-ring biosynthesis protein FlgA 2.09 2.38E-03 1.58# 1.08E-02
BPSL0271 flgC flagellar basal body rod protein FlgC 2.20 6.66E-03 1.75# 1.52E-02
BPSL0272 flgD flagellar basal body rod modification protein 2.12 7.33E-03 1.76# 1.43E-02
BPSL0273 flgE flagellar hook protein FlgE 1.88 3.02E-03 1.39# 1.22E-02
BPSL0274 flgF flagellar basal body rod protein FlgF 1.79 4.69E-03 1.29# 1.66E-02
BPSL0275 flgG flagellar basal body rod protein FlgG 1.92 5.66E-03 1.43# 1.64E-02
BPSL0276 flgH flagellar basal body L-ring protein 1.88 2.96E-03 1.44# 1.03E-02
BPSL0278 flgJ flagellar rod assembly protein/muramidase FlgJ 1.83 4.51E-03 1.27# 1.87E-02
BPSL0403 mce related protein 1.19 1.26E-03 1.22 7.78E-04
BPSL0812 bpeR TetR family regulatory protein 1.09 7.33E-03 1.08 8.20E-03
BPSL0814 bpeA RND family acriflavine resistance protein A
precursor
1.65 2.23E-03 1.56 2.22E-03
BPSL0815 bpeB RND family acriflavine resistance protein 1.84 7.63E-03 1.79 7.22E-03
BPSL1053 putative lipoprotein 0.48 3.05E-01 1.50 5.74E-03
BPSL1112 putative lipoprotein 1.54 1.55E-03 1.24 6.71E-03
BPSL1184 putative sugar-related transport, membrane protein 1.01 6.70E-03 0.88 1.37E-02
BPSL1185 protein of unknown function 3.95 3.83E-05 4.04 2.11E-05
BPSL1202 putative transport-related membrane protein 0.61 8.41E-02 1.93 2.32E-04
BPSL1203 putative carbonic anhydrase 0.63 6.17E-02 2.03 9.28E-05
BPSL1254 protein of unknown function 1.59 4.26E-03 1.75 2.10E-03
BPSL1289 osmB osmotically inducible lipoprotein B precursor 0.72 3.89E-02 1.66 2.80E-04
BPSL1387 protein of unknown function 1.09 1.34E-03 0.77 8.20E-03
BPSL1563 putative membrane protein of unknown
function
1.22 5.17E-04 1.68 4.16E-05
BPSL1564 putative transcriptional regulatory protein 0.50 1.17E-01 1.37 9.39E-04
BPSL1598 putative transport-related, membrane protein 0.28 3.17E-01 1.59 1.66E-04
BPSL1829 putative methyl-accepting chemotaxis protein 1.98 4.26E-03 1.34# 1.89E-02
BPSL1872 putative N-acetylmuramoyl-L-alanine amidase 1.07# 3.99E-02 1.47 9.64E-03
BPSL1931 protein of unknown function 0.83 2.35E-02 1.01 9.10E-03
BPSL2011 putative osmosis-related lipoprotein −0.35 2.54E-01 1.08 2.78E-03
BPSL2016 protein of unknown function 0.78 5.21E-02 1.30 5.35E-03
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Table 2 Genes with increased expression in either the bprR and/or bprS single mutants (Continued)
BPSL2017 di-haem cytochrome c peroxidase 0.67 1.09E-01 1.38 5.35E-03
BPSL2193 protein of unknown function 0.90 7.52E-03 1.12 2.10E-03
BPSL2282 protein of unknown function 0.62 6.86E-02 1.97 1.20E-04
BPSL2396 protein of unknown function 1.27 7.30E-03 1.30 5.74E-03
BPSL2397 protein of unknown function 1.46 2.48E-03 1.25 5.30E-03
BPSL2398 protein of unknown function 1.12# 1.09E-02 1.18 7.39E-03
BPSL2399 putative glycosyltransferase 1.36 1.55E-03 1.19 2.72E-03
BPSL2409 ABC transporter ATP binding protein 0.85 2.82E-02 1.09 8.00E-03
BPSL2466 protein of unknown function 0.76 1.43E-02 2.03 2.30E-05
BPSL2482 peptidase 1.25 2.38E-03 1.32 1.27E-03
BPSL2483 ribosome-associated GTPase 0.97 5.86E-03 1.01 4.35E-03
BPSL3254B protein of unknown function 1.63 1.22E-03 1.94 2.75E-04
BPSL3291 fliA flagellar biosynthesis sigma factor 1.86 2.45E-03 1.50 6.41E-03
BPSL3292 flhG flagellar biosynthesis protein FlhG 2.21 3.79E-03 1.74# 1.08E-02
BPSL3293 flhF flagellar biosynthesis regulator FlhF 2.23 1.83E-03 1.75 5.35E-03
BPSL3294 flhA flagellar biosynthesis protein FlhA 2.09 7.89E-03 1.67# 1.66E-02
BPSL3323 putative transferase 1.55 8.43E-03 1.13# 2.51E-02
BPSL3324 putative keto/oxo acyl-ACP synthase 1.51 7.17E-03 0.98 3.22E-02
BPSL3326 putative keto/oxo acyl-ACP synthase 1.78 8.43E-03 1.39# 1.99E-02
BPSL3327 putative short chain dehydrogenase 1.74 3.62E-03 1.26# 1.52E-02
BPSL3329 Rieske (2Fe-2S) domain-containing protein 1.31 7.21E-03 0.95 2.29E-02
BPSS0215 tar methyl-accepting chemotaxis protein 1.70 6.71E-03 1.35# 1.58E-02
BPSS0216 putative membrane protein of unknown function 1.12 4.45E-03 0.82 1.97E-02
BPSS0223 protein of unknown function 0.82 8.44E-03 1.44 2.34E-04
BPSS0236 ltaE L-allo-threonine aldolase 0.96 2.09E-02 1.20 6.20E-03
BPSS0264 protein of unknown function 1.02# 2.56E-02 1.36 6.20E-03
BPSS0298 transport related membrane protein 1.60 1.36E-03 1.07# 1.37E-02
BPSS0299 malM fatty-acid CoA ligase 2.20 8.23E-03 1.63# 2.27E-02
BPSS0300 malL malonyl CoA-acyl carrier protein 2.29 2.38E-03 1.60# 1.17E-02
BPSS0301 malK protein of unknown function 2.24 1.91E-03 1.60 9.10E-03
BPSS0302 malJ fatty acid biosynthesis-related CoA ligase 2.30 2.96E-03 1.66# 1.29E-02
BPSS0303 malI diaminopimelate decarboxylase 2.39 8.17E-04 1.81 2.78E-03
BPSS0304 malH protein of unknown function 2.60 3.60E-04 1.93 1.38E-03
BPSS0305 malG ketol-acid reductoisomerase 2.51 3.20E-04 1.95 9.39E-04
BPSS0306 malF multifunctional polyketide-peptide syntase 2.67 5.32E-04 2.14 1.38E-03
BPSS0307 malE gamma-aminobutyraldehyde dehydrogenase 2.81 1.53E-04 2.35 2.60E-04
BPSS0308 malD protein of unknown function 2.75 1.55E-04 2.23 3.46E-04
BPSS0309 malC peptide synthase regulatory protein 2.89 8.78E-05 2.33 2.10E-04
BPSS0310 malB protein of unknown function 2.98 1.53E-04 2.62 2.20E-04
BPSS0311 malA multifunctional polyketide-peptide syntase 3.10 5.17E-04 2.87 4.96E-04
BPSS0312 malR LuxR family transcriptional regulator 1.47 6.27E-04 1.12 2.72E-03
BPSS0317 monooxygenase 1.54 1.55E-03 2.38 6.99E-05
BPSS0325 putative membrane protein of unknown function 0.32 2.91E-01 1.07 3.74E-03
BPSS0337 protein of unknown function 1.38 1.24E-03 1.91 1.20E-04
BPSS0623 outer membrane efflux protein 2.09 5.17E-04 2.27 2.10E-04
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Table 2 Genes with increased expression in either the bprR and/or bprS single mutants (Continued)
BPSS0624 macB macrolide-specific ABC-type efflux carrier 1.95 1.61E-03 2.22 4.96E-04
BPSS0625 drug-efflux protein 1.97 6.27E-04 2.15 2.33E-04
BPSS0685 protein of unknown function 1.21 6.63E-04 0.89 5.35E-03
BPSS0686a Predicted 5,10-methylene tetrahydromethanopterin
reductase
3.39 1.14E-07 0.35 1.71E-01
BPSS0686aa protein of unknown function 5.16 8.78E-05 −0.47 5.88E-01
BPSS0687a sensor kinase protein 5.89 7.90E-09 1.46 2.89E-04
BPSS0688a response regulator protein 4.56 9.34E-09 4.70 7.98E-09
BPSS0689 protein of unknown function 7.12 7.90E-09 7.78 5.57E-09
BPSS0690 protein of unknown function 6.45 1.06E-08 6.49 9.89E-09
BPSS0692 fumarylacetoacetate (FAA) hydrolase family
protein
2.26 1.55E-04 2.16 2.10E-04
BPSS0693 fumarylacetoacetate (FAA) hydrolase family
protein
2.07 1.53E-04 1.88 2.10E-04
BPSS0694 hpcC 5-carboxymethyl-2-hydroxymuconate
semialdehyde dehydrogenase
2.14 2.48E-05 2.18 1.82E-05
BPSS0695 hpcB 3,4-dihydroxyphenylacetate 2,3-dioxygenase 1.81 8.07E-05 1.84 4.84E-05
BPSS0696 hpcD 5-carboxymethyl-2-hydroxymuconate delta-
isomerase
2.19 1.53E-04 1.98 2.44E-04
BPSS0697 hpcG 2-oxo-hepta-3-ene-1,7-dioic acid hydratase 1.85 2.01E-04 1.89 1.69E-04
BPSS0698 hpcH 2,4-dihydroxyhept-2-ene-1,7-dioic acid aldolase 2.01 1.55E-04 1.99 1.67E-04
BPSS0724 protein of unknown function 0.83 7.33E-03 1.09 1.38E-03
BPSS0755 LysR family regulatory protein 0.57 3.11E-02 1.03 1.23E-03
BPSS0796A H-NS-like protein 1.71 2.38E-03 4.39 1.27E-06
BPSS0797 IclR family regulatory protein 1.03 6.40E-02 3.95 1.96E-05
BPSS0798 protein of unknown function 0.68 1.60E-01 3.35 2.11E-05
BPSS0799 diguanylate phosphodiesterase 1.04 9.65E-03 4.48 1.31E-07
BPSS0828 protein of unknown function 0.82 3.54E-02 1.21 5.35E-03
BPSS0852 inosine-uridine preferring nucleoside hydrolase 1.60 6.57E-03 1.74 3.49E-03
BPSS0941 protein of unknown function 1.07 8.73E-03 1.33 2.78E-03
BPSS0946 penA beta-lactamase precursor 1.94 2.38E-03 2.65 2.44E-04
BPSS1038 protein of unknown function 0.04 9.47E-01 1.66 5.01E-03
BPSS1239 peptidase 0.33 6.92E-01 2.76 2.53E-03
BPSS1250 acetylpolyamine aminohydrolase 0.95 2.14E-02 1.10 9.81E-03
BPSS1275 RNA polymerase sigma factor 1.25 7.92E-03 1.51 2.99E-03
BPSS1296 O-methyltransferase-like protein 0.88 1.11E-02 1.05 4.84E-03
BPSS1553 bprP Transcriptional regulator 1.57 2.04E-03 1.19 8.84E-03
BPSS1554 bprQ Protein associated with bprP 1.43 1.28E-03 1.31 2.27E-03
BPSS1862 ABC transport system, ATP-binding protein 1.70 8.43E-03 1.71 7.39E-03
BPSS1866 lipoprotein 0.21 5.80E-01 1.44 2.10E-03
BPSS1867 protein of unknown function 1.42# 1.21E-02 2.20 9.10E-04
BPSS1980 protein of unknown function 0.66 1.61E-02 1.31 2.44E-04
BPSS1996 protein of unknown function 1.13 8.44E-02 2.84 8.95E-04
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unknown function), are located on chromosome 2 within
a predicted prophage. The remaining two genes differen-
tially expressed in the bprRS double mutant encoded a
predicted ATPase (bpsl0145) and a phage membrane pro-
tein (bpsl0146) that were within a large region on chromo-
some 1 also containing a predicted prophage.
Transcriptomic analyses of the bprS, bprR single gene
mutants
In order to identify gene expression changes that
resulted from perturbation of the BprRS system via in-
activation of bprS, encoding the SK, or bprR, encoding
the RR, we compared the transcriptomes of the bprS
and bprR mutants with the wild-type strain. A total of
170 genes were differentially expressed in one or both of
the single mutants and 57 genes showed increased ex-
pression and 16 reduced expression (≥2-fold change in
expression at FDR <0.01) in both the bprS mutant and
the bprR mutants (Fig. 3, Tables 2 and 3); thus, these
gene lists show a high degree of similarity (Fisher’s exact
test; P < 0.001). Moreover, when a slightly less stringent
FDR of <0.05 was applied to the initial gene list gener-
ated, 103 of the 171 genes identified were differentially
expressed in both the bprS mutant and the bprR mutant
(87 increased and 16 decreased) (Fig. 3, Tables 2 and 3).
Genes identified with increased expression in the bprS
and bprR single mutants included many involved in the
production of secondary metabolites; bpsl3323-3329 and
bpss0689-0690 involved in fatty acid biosynthesis,
bpss0692-0698 involved in the degradation of aromatic
compounds, and all the genes within the malleilactone
biosynthesis locus (bpss0298-bpss0312).
Two genes encoding methyl-accepting chemotaxis
proteins (MCPs) (bpsl1829 and tar) and at least 19 genes
required for flagella biosynthesis (including fliA encod-
ing the flagella biosynthesis sigma factor) showed in-
creased expression in the bprS single mutant; the
majority of these also showed increased expression in
the bprR mutant although mostly with FDR values be-
tween 0.01 and 0.05 (Tables 2 and 4). Genes involved in
antibiotic resistance were also increased in expression
and included bpeR (encoding a TetR family regulator),
bpeA and bpeB that together encode the resistance-
nodulation-division (RND) multidrug efflux pump
BpeAB-OprA [24]. Other genes involved in antibiotic re-
sistance that were over-expressed included the gene
bpsl2708, encoding a putative metallo-β-lactamase, and
penA that encodes a class A β-lactamase conferring
resistance to ceftazidime [25, 26]. Three genes (bpss0623,
macB and bpss0625) encoding an ABC transporter/type
I secretion system predicted to be involved in drug re-
sistance [27] were also over-expressed in the mutants.
Genes with decreased expression in both the bprR and
bprS mutant included five genes (bpss0515-bpss0520)
located within the type 6 secretion system cluster 2
(T6SS-2). This cluster encodes one of six T6SSs pro-
duced by B. pseudomallei (designated T6SS-1through to
T6SS-6) but only T6SS-1 has been determined to have a
role in virulence [28].
Importantly, a large number of regulatory genes were
identified as differentially expressed when the BprRS system
was perturbed by single gene inactivation. Regulatory genes
with increased expression in both the bprS and bprR single
mutants included fliA and bpeR (discussed above) and
Table 2 Genes with increased expression in either the bprR and/or bprS single mutants (Continued)
BPSS2162 protein of unknown function 0.42 5.50E-01 2.13 6.14E-03
BPSS2307 amidase 0.61 1.05E-01 1.47 1.92E-03
BPSS2308 protein of unknown function 1.01 1.26E-03 1.97 1.14E-05
Genes were identified as differentially expressed if they showed >2-fold expression change (log2 > 1.0) compared to the wild-type strain with a False Discovery
Rate (FDR) of <0.01. All significant gene expression changes are shown in bold and the locus tag, gene name and description are shown in bold when significant
expression changes were observed for both mutants
aIncreased RNA expression also observed in the bprRS double mutant (Table 1)
#Genes showing increased expression of >2-fold with a FDR of >0.01 and <0.05
Fig. 3 A Venn diagram showing the number of B. pseudomallei
genes with increased expression (up arrow) or with reduced expression
(down arrow) in each of the bprR, bprS and bprRS double mutants.
Genes were identified as differentially expressed if they showed >2-fold
expression change (log2 > 1.0) compared to the wild-type strain with a
False Discovery Rate (FDR) of <0.01. The total number of genes in each
mutant showing increased expression (>2-fold) with a more relaxed
FDR of <0.05 are shown in brackets
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Table 3 Genes with decreased expression in the bprR and/or bprS single mutants
Locus tag Gene
name
Gene product/description bprS mutant
Expression (log2)
bprS mutant
FDR
bprR mutant
Expression (log2)
bprR mutant
FDR
BPSL0153 putative phage protein −1.37 8.23E-03 −0.27 4.60E-01
BPSL0154 phage baseplate assembly protein −2.44 8.06E-03 −0.60 3.10E-01
BPSL0155 phage baseplate assembly protein −1.65 2.96E-03 −0.87 4.55E-02
BPSL0156 phage baseplate assembly protein −1.90 6.75E-04 −0.77 4.26E-02
BPSL0157 phage-encoded modification methylase −2.80 8.98E-04 −1.14 3.72E-02
BPSL0159 phage tail completion protein −0.90 1.70E-02 −1.72 1.33E-03
BPSL0169 phage terminase, endonuclease subunit −2.26 1.02E-03 −0.94 4.27E-02
BPSL0170 phage major capsid protein precursor −2.19 6.09E-03 −0.94 1.08E-01
BPSL0171 putative phage capsid scaffolding protein −2.48 8.20E-03 −0.93 1.59E-01
BPSL0347 putative insertion element protein −2.80 5.12E-03 −3.04 5.01E-03
BPSL0585 protein of unknown function −1.69 2.38E-03 −2.18 1.04E-03
BPSL0742 protein of unknown function −0.67 7.95E-02 −1.25 6.20E-03
BPSL0759 protein of unknown function −1.25 9.45E-03 −0.96 2.92E-02
BPSL0761 protein of unknown function −1.19 6.70E-03 −0.85 2.91E-02
BPSL1801 putative type-1 fimbrial protein −1.23 4.28E-03 −1.89 2.60E-04
BPSL2112 hydroxydechloroatrazine ethylaminohydrolase −1.47 4.03E-02 −2.16 7.22E-03
BPSL2113 putative purine catabolism-related protein −1.41 7.63E-03 −2.33 7.13E-04
BPSL2114 protein of unknown function −1.48 5.36E-03 −2.26 3.27E-04
BPSL2115 ureidoglycolate hydrolase −1.13 1.61E-02 −1.69 2.22E-03
BPSL2116 allantoicase −1.30 8.28E-03 −1.84 9.39E-04
BPSL2117 putative uricase −1.04 3.97E-02 −1.73 3.81E-03
BPSL2118 protein of unknown function −1.18 9.24E-03 −1.83 6.37E-04
BPSL2508 protein of unknown function −1.48 6.03E-03 −1.07 2.36E-02
BPSL2708 putative exported metallo-beta-lactamase-family
protein
−1.08 6.27E-04 −0.59 1.62E-02
BPSL2972 IclR family regulatory protein −1.02 2.38E-03 −0.82 8.20E-03
BPSL3171 protein of unknown function −1.25 6.57E-03 −0.92 2.71E-02
BPSS0063 dctD C4-dicarboxylate transport transcriptional
response regulator
−1.21 3.44E-03 −0.95 1.32E-02
BPSS0070 IS30 transposase −0.66 4.42E-02 −1.06 6.19E-03
BPSS0169 protein of unknown function −1.72 7.67E-03 −1.44 1.90E-02
BPSS0515 type VI secretion-associated protein, ImpA
family
−1.86 2.63E-03 −1.75 5.74E-03
BPSS0516 type VI secretion protein −1.79 8.28E-03 −1.98 9.46E-03
BPSS0517 EvpB protein of unknown function −2.03 1.85E-04 −1.76 5.84E-04
BPSS0518 type VI secretion protein −1.98 5.17E-04 −1.74 1.41E-03
BPSS0520 type VI secretion protein −1.36 9.44E-04 −1.27 2.01E-03
BPSS1034 protein of unknown function −1.12 7.89E-03 −1.69 8.11E-04
BPSS1035 protein of unknown function −1.74 5.66E-03 −2.24 2.78E-03
BPSS1080 bacteriophage baseplate assembly protein J −1.47 8.24E-03 −0.54 1.90E-01
BPSS1085 bacteriophage major tail tube protein −1.47 7.30E-03 −0.75 8.02E-02
BPSS1588 protein of unknown function −1.57 3.16E-02 −2.21 5.01E-03
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malR (bpss0312), encoding a regulator that shares identity
(97 %) with MalR in Burkholderia thailandensis, an orphan
LuxR homolog that activates the malleilactone biosynthesis
genes independently of acyl-homoserine lactone and
quorum sensing systems [29, 30]. The genes bprP
(bpss1553), encoding a transmembrane regulator, and
the adjacent gene bprQ, encoding a transmembrane
protein, involved in the control of the BsaN virulence
regulon were also over-expressed. Importantly, the
BsaN virulence regulon includes genes encoding the
type III secretion system locus 3 (TTSS3) [31, 32]. The
expression of bpss0799 in both the bprR and bprS sin-
gle mutants was also increased (Table 4); the encoded
protein contains an EAL domain and shares significant
identity with cyclic diguanylate phosphodiesterases,
which are known to control motility and biofilm for-
mation in a number of bacteria [33]. Other regulatory
genes with increased expression but in only the bprR
mutant were bpss0797 encoding an IclR family pro-
tein, bpss0755 encoding a LysR family protein, and
bpsl1564 that encodes a putative transcriptional regu-
latory protein (Table 4). Only one regulatory gene
(bpss00070, encoding an IS30 transposase) had de-
creased expression in the bprR mutant. Regulatory
genes that were reduced in expression but only in the
bprS single mutant included bpsl2972, encoding an
Table 3 Genes with decreased expression in the bprR and/or bprS single mutants (Continued)
BPSS1740 lipB lipase chaperone −0.83 3.87E-02 −1.41 5.01E-03
BPSS2136 Family S43 non-peptidase protein −1.24 2.38E-03 −1.16 3.97E-03
BPSS2138 oppD oligopeptide transport ATP-binding ABC
transport protein
−1.11 9.63E-03 −1.20 9.13E-03
BPSS2296 transport protein −2.21 3.62E-03 −1.87 1.14E-02
Genes were identified as differentially expressed if they showed >2-fold expression change (log2 < −1.0) compared to the wild-type strain with a False Discovery
Rate (FDR) of <0.01. All significant gene expression changes are shown in bold and the locus tag, gene name and description are shown in bold when significant
expression changes were observed for both mutants
Table 4 Regulatory genes differentially expressed in the bprR and/or bprS single mutants
Locus tag/gene Description/predicted function Expression in
bprS mutant
Expression in
bprR mutant
Two component signal transduction systems Class/Function
BPSL1829 methyl-accepting chemotaxis
protein
Increased Increased# MCP/Chemotaxis
BPSS0063 dctD C4-dicarboxylate transport protein Decreased NS RR/Receiver
BPSS0215 tar methyl-accepting
chemotaxis protein
Increased Increased# MCP/Chemotaxis
BPSS0687 bprS sensor kinase protein Increased Increased HK/Transmitter
BPSS0688 bprR response regulator protein Increased Increased RR/Receiver
One component regulators Domain-input Domain-output
BPSL0812 bpeR TetR family regulatory protein Increased Increased Not known TetR_N-DNA binding
BPSL1564 transcriptional regulatory protein NS Increased Not known HTH_26-DNA binding
BPSL2972 IclR family regulatory protein Decreased NS IclR/Small-molecule binding HTH_IclR-DNA binding
BPSL3291 fliA flagellar biosynthesis sigma factor Increased Increased Not known Sigma70 -DNA binding
BPSS0070 IS30 transposase NS Decreased Not known HTH_38-DNA binding
BPSS0312 malR
LuxR transcriptional regulator Increased Increased Autoind_bind- Small-molecule
binding
GerE-DNA binding
BPSS0755 LysR family regulatory protein NS Increased LysR_substrate- Small-molecule
binding
HTH_1-DNA binding
BPSS0797 IclR family regulatory protein NS Increased IclR/Small-molecule binding HTH_IclR-DNA binding
BPSS0799 Diguanylate phosphodiesterase Increased Increased EAL/Di-guanylate cyclase
BPSS1553 bprP Transcriptional regulator Increased Increased Trans_reg_C/DNA-binding
Genes were identified as differentially expressed if they showed >2-fold expression change (log2 < −1.0) compared to the wild-type strain with a False Discovery
Rate (FDR) of <0.01
#Genes showing increased expression of >2-fold with a FDR of >0.01 and <0.05
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IclR family protein, and dctD, encoding a C4-
dicarboxylate transport transcriptional response regu-
lator (Table 4).
Perturbation of the BprRS TCSTS affects B. pseudomallei
motility
In the mutants with a single inactivation in either bprS
or bprR, 21 genes involved in flagella biosynthesis were
increased in expression, located in four different loca-
tions on chromosome 1 (Table 2). In addition, two genes
encoding methyl-accepting chemotaxis proteins
(bpsl1829 and tar) showed increased expression, and
there was decreased expression of the type-1 fimbrial
gene, bpsl1801 (Table 3) predicted to be involved in at-
tachment to surfaces. Accordingly, we analysed the bprS
mutants (bprS::Tn5 and the bprS directed mutant), the
bprR directed mutant, the parent strain K96243, as well
as the bprRS double mutant, for their ability to migrate
or swarm in a coordinated manner on solid medium.
The parent strain K96243 and the bprRS double mutant
both demonstrated a capacity for rapid swarming, with
the leading edge of the swarming population migrating
to the edge of the agar plate (diameter 80 mm) after
18 h at 37 °C (Fig. 4). However, all strains with either
bprS or bprR inactivated demonstrated a significantly re-
duced ability to swarm in a coordinated manner (Fig. 4).
To confirm that the reduced swarming motility was due
to perturbation of the BprRS system, we complemented
the bprS directed mutant with the complete bprRS op-
eron in trans. Interestingly, we were unable to clone ei-
ther bprS or bprR into the multicopy plasmid pBHR1
alone. Swarming motility was fully restored in the
bprS(bprRS) complemented strain, whereas the bprS mu-
tant harbouring empty vector (pBHR1) alone retained
the reduced motility phenotype (Fig. 4). These data show
that inactivation of a single component in the BprRS
TCSTS can reduce the swarming ability of B. pseudomallei.
Discussion
We have identified a putative TCSTS in B. pseudomallei
strain K96243 that is encoded by bprS (bpss0687) encod-
ing the SK, and bprR (bpss0688) encoding the RR. Inacti-
vation of the entire BprRS system did not result in
changes to virulence or motility, and RNA expression
analysis of the bprRS double mutant identified very few
genes that were differentially expressed compared to the
expression in the parent strain K96243. Genes identified
as differentially expressed in the bprRS double mutant
included one (bpss0686) adjacent to the bprS gene, en-
coding a predicted 5, 10-methylene tetrahydrometha-
nopterin reductase that is required for one carbon
metabolism [23]. Five genes that encoded phage-related
proteins were also identified. Thus, our analysis suggests
that the BprRS TCSTS regulon is small but it is possible
that under different growth conditions, such as during
growth in a host or the environment, other genes may
be identified that belong to the BprRS regulon.
In contrast, inactivation of a single component (bprS
or bprR) of the BprRS TCSTS resulted in the differential
expression of a large number of genes. More than 70
genes were differentially expressed in both the bprS and
bprR mutant and included those involved in flagella bio-
synthesis, malleilactone biosynthesis, antibiotic resist-
ance, chemotaxis and regulation. In addition, phenotypic
assays showed that the bprS and bprR mutants displayed
reduced growth in mice and reduced swarming motility.
Fig. 4 The B. pseudomallei bprS and bprR mutants display reduced
motility. Swarming motility was measured on agar plates grown at
37 °C for 18 h. Panel a, selected images of motility plates and Panel
b, quantification of the motility data. Strains are B. pseudomallei wild-
type (WT), directed bprS mutant (bprS), bprS transposon mutant
(bprS::Tn5), bprR mutant (bprR), bprRS double mutant (bprRS),
complemented bprS mutant (bprS(bprRS)), bprS mutant containing
empty vector (bprS(pBHR1)) and a non-motile fliC mutant control
(panel b only). Data are mean ± SEM. * = P < 0.01
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Together, these results clearly demonstrate that perturb-
ation of the BprRS system, but not inactivation of the
whole system, attenuates B. pseudomallei. We hypothesize
that the changes observed as a result of perturbation of
the BprRS TCSTS arise through cross-regulation with one
or more of the 60 TCSTS encoded on the B. pseudomallei
genome [15]. A number of interactions between TCSTS
have been identified in Escherichia coli; in vitro phosphor-
ylation assays showed that phosphorylation of RRs by
non-cognate SKs was observed for at least 21 pairs [34].
While most E. coli cross-talk interactions are weak [34],
strong cross-talk has been observed between a number of
systems, including CreC and PhoB and the PmrA/B and
QseB/C systems of E. coli [35, 36] Interactions between
PhoB, PmrA/B and QseB/C happen at multiple levels in-
cluding phosphorylation, dephosphorylation and DNA
binding. The E. coli QseC SK normally acts to dephos-
phorylate (and deactivate) its cognate RR QseB, but QseB
can be phosphorylated by PmrB at relatively high levels
[36] and the binding of both RRs at the qseBC promoter is
likely to be required for normal gene expression. In the
absence of QseC the phosphorylating activity of PmrB on
QseB is uncontrolled, leading to increased expression of
the QseBC TCSTS and decreased expression of a range of
virulence genes including those involved in pilin and fla-
gellin synthesis. Importantly, while an E. coli qseC mutant
was non-motile and attenuated for virulence, the single
qseB and the double qseBC mutants showed wild-type
virulence and motility [37]. Cross-regulation has been im-
plicated in at least three E. coli TCSTS that affect flagella
synthesis and motility, including predicted interactions be-
tween ArcAB and another unidentified TCSTS [38].
Therefore, we propose that in the absence of both BprR
and BprS (i.e. the bprRS double mutant) only the expres-
sion of genes within the BprRS regulon is affected. How-
ever, in the absence of BprS, BprR is phosphorylated by
one or more, non-cognate sensor kinases and interacts
with genes outside the BprRS regulon. Conversely, we pre-
dict that in the absence of BprR, BprS phosphorylates one
or more, non-cognate response regulators. Moreover,
given that a large subset of genes was differentially
expressed in both the bprR and bprS mutants, we propose
that the majority of cross-talk occurs largely with a single,
as yet unidentified, TCSTS cognate pair. This cross-talk
then leads to a cascade of dysregulation, including altered
expression of genes encoding other regulators.
Phenotypic analysis of the mutants revealed that the
bprS and bprR mutants were attenuated for swarming
motility. In both mutants many flagella biosynthesis
genes showed increased expression compared to the
wild-type strain; suggesting that altered motility resulted
from incorrect levels of flagella proteins or dysregulated
timing of expression. Furthermore, genes within the
flagella-associated locus, including fliC encoding the
flagella subunit, were not changed in expression com-
pared to that in the parent strain K96243 supporting the
proposition that the altered motility of the BprS and
BprR mutants may have been affected by an imbalance
in the expression of the flagella biosynthesis and struc-
tural components. In E. coli and other bacteria, flagella
synthesis involves the action of numerous and complex
TCSTS interactions, and we predict similar interactions
between regulatory factors is also likely to be essential
for the co-ordinated movement of B. pseudomallei. The
gene bpss0799, encoding a protein with an EAL domain
characteristic of cyclic diguanylate phosphodiesterases,
was increased in expression in both the bprS and bprR
mutants. Cyclic diguanylate phosphodiesterases nega-
tively control levels of bis-(3′-5′)-cyclic dimeric guano-
sine monophosphate (c-di-GMP) and, together with the
positive regulator diguanylate cyclase, initiate the c-di-
GMP signalling system in bacteria. The global second
messenger c-di-GMP then binds to specific effector mol-
ecules that target, and subsequently affect the expression
of a wide range of genes involved in cellular functions
including motility, biofilm formation and the production
of fimbriae [33]. A previous study identified another B.
pseudomallei gene (cdpA or bpsl1263) as encoding the
cyclic diguanylate phosphodiesterase involved in flagella
function and motility [39]. However, our own bioinfor-
matic analysis (data not shown) indicates that bpsl1263
encodes a protein with both an EAL and a GGDEF do-
main, the latter domain being characteristic of diguany-
late cyclases. Other regulatory genes with increased
expression in the bprS and bprR mutants included two
genes encoding predicted MCPs, bpsl1829 and tar.
MCPs are the trans-membrane sensor proteins of the
chemotaxis pathway that controls bacterial movement in
response to available nutrients or other environmental
stimuli [40]. In E. coli, MCPs directly transfer phosphate
to the TCSTS SK CheA that then transfers the phos-
phate to one of two RRs, CheY or CheB. Phosphorylated
CheY interacts directly with the flagella motor and
causes a directional change, whereas phosphorylated
CheB acts a methylesterase on the signalling MCP and
modulates the amount of signal [41]. The MCP Tar sen-
sors induce bacterial cells to move towards aspartate/
maltose and away from nickel/cobalt [42]. Bioinformatic
analysis did not provide any information on the type of
sensor the bpsl1829 gene encodes, but we predict that
dysregulation of the expression of either MCP is likely
to have an effect on motility. Although no studies have
been conducted on chemotaxis mutants in any Burkhol-
deria species, a study in a close relative, Ralstonia sola-
nacearum, showed that a cheA mutant displayed
significantly reduced virulence [43].
The genes bprP and bprQ, involved in the BsaN viru-
lence regulon, both displayed increased expression when
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the BprRS TCSTS was perturbed. A recent transcrip-
tomic study of a B. pseudomallei bsaN deletion mutant
elucidated components of the BsaN virulence-associated
regulatory system [32]. It is proposed that BprP directly
activates the Ara-C like regulatory protein BsaN that, to-
gether with the T3SS3 chaperone BicA, act as a dual-
function regulatory complex that controls the expression
of the T6SS-1 (via activation of the VirAG TCSTS) and
the T3SS3 effectors (bopA, bopC and bopE). In addition,
in the bsaN mutant the TTSS3 genes showed increased
expression, while the genes involved in malleilactone
(bpss0303-0311) and flagella biosynthesis (bpsl0281,
bpsl3319, bpsl3320, bpsl3321) showed decreased expres-
sion [32]. In our study, we observed an increase in ex-
pression of bprP and bprQ, but not the gene encoding
the chaperone BicA. We also observed an increase in ex-
pression of malleilactone-associated and flagella-
associated genes, but no significant change in expression
of genes associated with the T3SS3 and T6SS-1. Never-
theless, it is possible that an imbalance in the expression
of the proteins that initiate the transcription of bsaN
(BprP/BicA) may have an effect on the expression of
some genes within the BsaN regulon.
Perturbation of the BprRS TCSTS reduced the in vivo
fitness of B. pseudomallei and this may, or may not have
been directly associated with the loss of motility. An ini-
tial report demonstrated that a non-flagellated fliC mu-
tant constructed in B. pseudomallei strain 1026b was
not attenuated for virulence in BALB/c mice, diabetic
rats or Syrian hamsters [44, 45]. In contrast, a fliC mu-
tant of a more virulent strain of B. pseudomallei (KHW)
was attenuated for virulence in BALB/c mice [46].
Conclusions
Phenotypic and transcriptomic analyses of a newly iden-
tified TCSTS BprRS, revealed that perturbation of the
system via inactivation of the SK BprS or the RR BprR
led to a reduction in virulence and reduced motility, as
well as a wide range of gene expression changes. Our re-
sults support the concept that B. pseudomallei TCSTS
regulatory networks can interact and show that selective
perturbation of these systems can lead to attenuation of
B. pseudomallei. Together our results highlight the need
for further systematic studies of B. pseudomallei TCSTS
regulation and show that targeting a single TCSTS com-
ponent can attenuate virulence.
Methods
Bacterial strains, plasmids and culture conditions
The B. pseudomallei strain K96243 is a human clinical
isolate obtained from Thailand [15]. B. pseudomallei di-
rected mutants were generated by double cross-over in-
sertional mutagenesis using recombinant derivatives of
the λ pir-dependent plasmid pDM4 [47]. All pDM4
derivatives were maintained in E. coli SM10 λ pir (thi
thr leu tonA lacY supE recA RP4-2-Tc::Mu::Km pir), or
E. coli S17-1 λ pir (thi pro hsdR hsdM1 recA RP4-2-
Tc::Mu-Km::Tn7 pir). For some clonings, pBlueScriptSK-
(Stratagene) was used as an intermediate vector prior to
transfer of the insert into pDM4. The pBlueScript deriv-
atives were grown in E. coli DH5α cells (F− endA1
hsdR17 (rk
−mk
−) glnV44 thi-1 λ− recA1 gyrA96 relA1
Δ(argF- lacZYA)U196 ϕ80dlacZ ΔM15). The tetracyc-
line resistance gene tetA(C) was used for selection of B.
pseudomallei mutants and was isolated from either
pUTminiTn5Tc (Biomedal S. L., Spain) or pWH1266
[48]. For complementation, the BprRS operon was
cloned into the plasmid pBHR1, a derivative of the
mobilizable broad-host-range plasmid pBBR1 [49]. All E.
coli strains were routinely grown on lysogeny broth (LB)
medium with or without selection. B. pseudomallei
K96243 and derivatives were grown using either LB,
yeast-tryptone medium (2YT), minimal medium (M9),
or Ashdown’s medium (containing 64 μg/ml gentami-
cin). All strains were grown at 37 °C (liquid cultures
with 200 rpm agitation).
Construction and screening of B. pseudomallei signature-
tagged mutagenesis library
A B. pseudomallei signature-tagged mutagenesis library
was constructed using a modified miniTn5 transposon
(Biomedal S.L., Spain). Briefly, 42 unique DNA-tags were
amplified from the STM-adapted Tn916 transposons
generated by Harper et al. [50] and cloned into the
unique NotI site of pUTminiTn5Tc. The 42 uniquely-
tagged transposons were then separately introduced into
B. pseudomallei by conjugation and pools of 42 mutants
collected. Each STM pool was then screened for reduced
in vivo growth in BALB/c mice [51]. An input pool in-
oculum of approximately 2 × 108 CFU was used to in-
oculate two 8–10 week old, female BALB/c mice by the
i.n. route. DNA recovered from pooled input colonies
and pooled output colonies (harvested from spleen), was
used to generate digoxygenin-labelled (Roche) DNA
probes representing tags present in each sample. La-
belled probes were then used in dot blot hybridizations
to determine the presence/absence of each mutant in in-
put and output pools as described previously [50].
Generation of bprS, bprR and bprRS double cross-over
mutants
The bprS, bprR and bprRS mutants were constructed by
double cross-over insertional mutagenesis using the λ
pir-dependent vector pDM4 [47] which carries a chlor-
amphenicol resistance gene for selection and the
counter-selectable sacB gene. To generate the bprS mu-
tagenesis construct, an internal fragment of bprS was
disrupted by cloning of the miniTn5 tetA(C) gene into
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the bprS BglII site. Insertion of the tetA(C) gene at this
BglII site results in the termination of BprS translation
at the second transmembrane region (Fig. 1). Briefly, the
primers BAP4787 (5′ TTCGTGCTGCAGGATTATC
TCGAACGCCATCC 3′) containing a PstI site, and
BAP4788 (5′ CGAATCTCTAGAGTGGAACGGCTCG
AACAC 3′) containing an XbaI site, were used to amp-
lify a 981 bp PCR product from within the B. pseudo-
mallei K96243 bprS gene. This PCR fragment,
containing an internal BglII site, was digested with PstI
and XbaI and ligated into similarly digested pDM4.
Primers BAP3325 (5′ CGGCTTAGATCTAGGTCGA
GGTGGCC 3′) and BAP4629 (5′ TCCACCAGATC-
TATTTGCCGACTACCTTGGTG 3′), both containing a
BglII site, were used to amplify the miniTn5 tetA(C)
gene. This PCR product and pDM4 containing the bprS
internal fragment were digested with BglII and ligated to
generate the plasmid pAL603 which was then intro-
duced by transformation into E. coli SM10 λ pir.
For generation of the bprR mutagenesis construct,
pBluescriptSK- was used as an intermediate plasmid
prior to cloning into pDM4. Primers BAP6698 (5′ GA
ACACCCCGGGCGCGAGATCGACATGCCCGGACAC
GCC 3′) containing an XmaI site, and BAP6699 (5′
CGTCGTACTAGTACATGAAGCCGAAGCCCTCGTT
GCCG 3′) containing an SpeI site, were used to amplify
a 1648 bp PCR product from B. pseudomallei K96243
encompassing the entire bprR gene, 687 bp of up-
stream and 241 bp of downstream DNA. This PCR
product, containing an internal AatII site within bprR
(Fig. 1a) was digested with XmaI and SpeI and ligated
into similarly digested pBluescriptSK-. Primers BAP6700
(5′ AAAACAGACGTCTTGCTAACGCAGT 3′) and
BAP6701 (5′ AAAAATGACGTCAGTGGTGAATCC 3′),
both containing an AatII site, were used to amplify the
tetA(C) gene from pWH1266. This product and the
pBluescriptSK- derivative containing the bprR fragment
were digested with AatII and ligated to generate the
plasmid pBluescriptSK::bprR-tet which was then intro-
duced into E. coli DH5α by transformation. This
insertion of the tetracycline resistance gene at the in-
ternal AatII site causes a truncation of bprR within
the initial receiver domain (Fig. 1a). The fragment
containing the disrupted bprR was released from
pBluescriptSK::bprR-tet by digestion with XmaI and
SpeI and ligated into pDM4, generating the plasmid
pAL1067 which was then introduced into E. coli
SM10 λ pir cells.
To generate the bprRS double mutant, up- and down-
stream regions encompassing the 5′ and 3′ ends of bprR
and bprS respectively were cloned into pBluescriptSK-,
with the tetA(C) gene from miniTn5 gene inserted be-
tween the two fragments. Insertion of this construct into
the genome leads to deletion of a 3′ segment of bprR
(encoding part of the receiver domain and all of the ef-
fector domain) as well as deletion of a 5′ segment of
bprS (encoding both transmembrane regions and the
HAMP and HisKA domains) (Fig. 1b). Briefly, primers
BAP6704 (5′ TCGACGCCCGGGTCACCGAGCTGCT-
GACGATCGGC 3′) containing an XmaI site, and
BAP6705 (5′ CGGCGCACTAGTTATCAGACCGAC-
TACGCGCC 3′), containing a SpeI site, were used to
amplify a 973 bp PCR fragment including the 3′ end of
bprS and down-stream flanking DNA. This product was
digested with appropriate enzymes and ligated into
pBluescriptSK- digested with XmaI and SpeI and intro-
duced into DH5α cells. Primers BAP6685 (5′ AAAACA-
GAATTCTTGCTAACGCAGT 3′) and BAP6686 (5′
AAAAATGAATTCAGTGGTGAATCC 3′), both con-
taining an EcoRI site, were used to amplify the tetA(C)
gene from pWH1266. This product and pBluescriptSK-
containing the DNA fragment containing bprS and
flanking region were digested with EcoRI, ligated and
introduced into E. coli DH5α. Primers BAP6702 (5′
AGCGGCGGGCCCCCGCATGCACCGAGCCC 3′) con-
taining an ApaI site, and BAP6703 (5′ GAGGCCATC-
GATTTGATCGTAGACGTCCG 3′) containing a ClaI
site, were used to amplify a 1021 bp PCR product
encompassing the 5′ end of bprR and up-stream flank-
ing DNA. This product was digested with ApaI and
ClaI and ligated into the similarly digested pBlue-
scriptSK- containing bprS plus flanking region and the
tetA(C) gene, and then introduced into E. coli DH5α
cells, generating the plasmid pAL1062. This plasmid
was digested with ApaI and SpeI and the fragment con-
taining bprR-tet-bprS was ligated into pDM4. The
resulting plasmid, designated pAL1066, was then intro-
duced into E. coli SM10 λ pir cells.
Each of the recombinant plasmids pAL603,
pAL1067 and pAL1066 was mobilised from E. coli
SM10 λ pir into B. pseudomallei K96243 by conjuga-
tion and putative double cross-over mutants were
selected on LB agar containing gentamicin (8 μg/mL)
and tetracycline (25 μg/mL). All mutations were
confirmed by PCR and sequence analysis (data not
shown).
Complementation of the bprS mutant
The bprS mutant was complemented by cloning an in-
tact copy of the bprRS operon into the multicopy plas-
mid pBHR1. Primers BAP7136 (5′ CGGCGCTTTAA
AGGCTCGATACTGACTGCTGCCGGC 3′) containing
a DraI site, and BAP7137 (5′ CGCGCGCCATGGAT
CGTCTGACGGCCGAAACC 3′) containing an NcoI
site, were used to amplify a 2483 bp PCR product from
B. pseudomallei K96243. This fragment encoded bprS
and bprR as well as 353 bp of the upstream region pre-
dicted to contain the bprRS promoter. The PCR
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product was digested with DraI and NcoI and ligated
into similarly digested pBHR1, disrupting the cat gene
and generating the plasmid pBHR1::bprRS. This plas-
mid was then introduced into E. coli S-17 λ pir and
kanamycin resistant, chloramphenicol sensitive clones
selected. The pBHR1::bprRS plasmid and empty pBHR1
(negative control) were separately mobilised from E.
coli S-17 into the bprS mutant by conjugation. Recom-
binants containing the pBHR1::bprRS plasmid were se-
lected on LB agar containing kanamycin (1000 μg/mL)
and tetracycline (25 μg/mL) while those containing the
empty pBHR1 plasmid were selected on LB agar
containing kanamycin (1000 μg/mL), tetracycline
(25 μg/mL) and chloramphenicol (40 μg/mL). Strains
containing the correct plasmids were identified by PCR
and nucleotide sequence analysis (data not shown).
Neither bprR nor bprS alone could be cloned into the
pBHR1 plasmid despite numerous attempts.
Competitive in vivo growth assays
Overnight cultures of B. pseudomallei wild-type parent
strain K96243 and the bprS mutant were grown in LB to
an optical density at 600 nm (OD600) of 0.2. Equal vol-
umes of K96243 and bprS mutant culture were combined
and 20 μl (containing approximately 4 × 105 CFU) of an
appropriate dilution was used to infect three 6–8 week-
old female BALB/c mice by the i.n. route. After 24 h, mice
were euthanized in accordance with animal ethics require-
ments. Spleens were harvested, homogenised in phosphate-
buffered saline pH= 7.2 (PBS) and plated onto LB agar.
After growth at 37 °C for 24 h, 100 colonies from these in
vivo growth plates and 100 colonies representing the input
culture were patched onto LB agar with or without tetra-
cycline (25 μg/ml) to determine the proportion of bprS mu-
tant to K96243 wild-type bacteria. The competitive index
was calculated as the proportion of mutant to wild-type
bacteria recovered from the mouse spleens divided by the
proportion of mutant to wild-type bacteria present in the
input inoculum.
Virulence assays
Overnight cultures of the parent strain K96243 and the
bprS, bprR and bprRS mutants were subcultured in fresh
medium with appropriate antibiotics and grown to mid-
log phase to an OD600 of 0.8 (equivalent to ~5.0 ×
108 CFU/ml). For the ID50 assays, groups of five 8–10
week-old BALB/c mice were either inoculated i.n (1.0 ×
106 CFU in 20 μl volume) or injected i.p (1.0 × 103 CFU
in 200 μl volume) with LB containing mid-exponential
phase bacteria. For the direct virulence assays, groups of
nine 6–8 week-old, female BALB/c mice were infected
i.n. with 20 μl doses containing approximately 5.0 ×
104 CFU. Mice were monitored for 10 days for signs of
disease and euthanized at the end of the experiment or
when moribund, in accordance with animal ethics
requirements. The ID50 for the parent strain K96243
and mutant strain was determined using the calculation
described by Reed and Muench [52] based on cumula-
tive moribund infections. For direct virulence assays, dif-
ferences in survival were calculated using Fisher’s exact
test and differences in time to death determined using
the log-rank Mantel-Cox test. Spleens from three mice
in each group were harvested, homogenised in PBS and
plated onto LB agar. The stability of the mutants was
assessed by patching the recovered colonies onto agar
plates with or without tetracycline (25 μg/ml). All of the
mutations were stable over the time course of the
experiment. The virulence of the complementation
strain bprS(bprRS) could not be assessed as the comple-
mentation plasmid was highly unstable in the absence of
antibiotic selection (>90 % plasmid loss over 16 h).
RNA purification
B. pseudomallei parent strain K96243 and the directed
bprS, bprR and bprRS mutants were grown overnight at
37 °C in LB with appropriate antibiotics (K96243 in gen-
tamicin 64 μg/ml; mutants in gentamicin 64 μg/ml and
tetracycline 25 μg/ml). Strains were subcultured 1/50
into fresh antibiotic-free medium and grown at 37 °C
with shaking (200 rpm) to an OD600 of 0.5. The cells
were harvested by centrifugation, and RNA purified
using Trizol reagent (Gibco/BRL) as specified by the
manufacturer. RNA was DNase treated using the
TURBO DNA-free kit (Ambion), followed by processing
with a QIAGEN RNeasy kit clean-up with on-column
DNase digestion as per the manufacturer’s instructions.
High-throughput RNA sequencing
Double-stranded cDNA synthesis and high-throughput
RNA-seq were performed as described previously [53].
For each strain three biological replicates were sequenced.
Trimmed sequence reads were aligned to the B. pseudo-
mallei K96423 genome sequence using SHRiMP [54] and
normalised read counts were compared using voom and
limma as described previously [53]. For each replicate
sample, between 6.4 million and 14.0 million sequence
reads were mapped uniquely to the K96423 genome se-
quence. The RNA-seq data is available at the NCBI Gene
Expression Omnibus; accession number GSE77970. Differ-
entially expressed genes were identified as those with a
greater than 2-fold change in expression (1.0 log2) across
all replicates at a false discovery rate (FDR) of <0.01.
Swarming motility assays
Swarming agar plates were prepared fresh on the day of
the assay using the modified protocol of Tunpiboonsak
et al. [55]. Briefly, plates were prepared using 0.5 %w/v
agar-agar (Merck), 8 g/L nutrient broth No.2 (Oxoid)
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and 5 g/L D(+)- glucose (dextrose) (May and Baker) and
dried carefully to give constant moisture content. Over-
night cultures of B. pseudomallei parent strain K96243
and mutant strains were subcultured 1/50 into fresh
medium with appropriate antibiotics (no selection for
parent strain, 25 μg/ml tetracycline for all mutants and
complemented mutants) and grown at 37 °C with shak-
ing (200 rpm) to late exponential phase (OD600 of ~2.5).
A 5 μl volume of each culture was spotted onto the
centre of a swarming agar plate which was then incu-
bated at 37 °C for 18 h in the dark. The diameter of the
swarming population was then measured. Statistical ana-
lysis of swarming distance was determined by Student’s
t-test with a P-value of <0.05 considered significant.
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